Abingworth
No summary available yet.
Here's the deal: Abingworth got acquired by Carlyle in 2022 for $2 billion AUM, which means you're now dealing with a PE-backed entity, not an independent VC. This changes the dynamic entirely. The good news? They have serious biotech chops - 179 companies invested, 70 IPOs, 46 M&As, and their portfolio companies have secured 26 FDA approvals in the last 9 years alone. That's not marketing fluff, that's real execution. Founders consistently praise them as 'very engaged partners' with 'deep knowledge of the industry' and 'extensive networks' - the CEO testimonials are unusually glowing for biotech VCs. They've innovated with VIPEs (Venture Investments in Public Equities) for undervalued <$200M market cap biotechs, plus clinical co-development - so they're not just writing checks, they're creating new funding mechanisms. The Carlyle backing gives them serious firepower, but it also means they're playing with institutional money that has different return expectations than traditional VC funds.
- —Best for: Late-stage biotechs needing serious capital and regulatory expertise
- —Known for: Strong founder relationships and innovative funding structures like VIPEs
- —Watch out for: Now PE-backed by Carlyle, so expect institutional-grade due diligence
Abingworth invests across three broad strategic areas: seed and early stage, development stage (including VIPEs and public markets) and clinical co-development, with over 30 years of experience investing in novel life science technologies. They understand how challenging it can be to turn a great idea into a great company and are comfortable evaluating and taking significant scientific risks.
Focus is heavily life sciences (108 investments) vs high tech (17 investments), with clinical co-development targeting drugs in or through Phase 3 testing with high probability of reaching approval and successful commercialization within a few years. Partners with pharma giants like AstraZeneca, Eisai and Pfizer on co-development deals.
Recently promoted to Head of Life Sciences and CIO, worked closely with Kurt von Emster for seven years and has demonstrated the vision and leadership to continue Abingworth's 53 years of successful life sciences investing. Known for deep scientific insight and analytical expertise.
Exceptional investor who made significant contributions to Abingworth since joining in 2015, led the firm for eleven years including expansion into clinical co-development and strategic relationship with Carlyle. His leadership has strengthened and grown Abingworth significantly.
Brings over 20 years of life sciences investing and executive experience, was most recently a Growth Partner with Flagship Pioneering, previously Managing Partner of Gurnet Point Capital and CEO of Stealth BioTherapeutics. Also member of venture capital team at Morningside.
Have a specific question about Abingworth?
Ask Bernie →